-
-
-
-
-
-
-
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
-
-
-
-
-
-
-
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
-
-
-
-
-
-
-
Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
-
-
-
-
-
-
-
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
-
-
-
-
-
-
-
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
REPEAT -- Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
After-Hours Movers 11/19: (FLNT) (BCRX) (STNG) Higher; (URBN) (MUX) (ORGO) Lower (more...)
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

